510(k) K221813
K221813 is an FDA 510(k) premarket notification submitted by Nova Biomedical Corporation for the device "Nova Allegro UACR Assay, Nova Allegro Analyzer". The FDA issued a decision of Substantially Equivalent on November 19, 2024. The device falls under product code CGX (Alkaline Picrate, Colorimetry, Creatinine), a Class II device regulated under 21 CFR 862.1225. Nova Biomedical Corporation has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- November 19, 2024
- Date Received
- June 22, 2022
- Clearance Type
- Dual Track
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Alkaline Picrate, Colorimetry, Creatinine
- Device Class
- Class II
- Regulation Number
- 862.1225
- Review Panel
- CH
- Submission Type